SINTX Technologies provided a mid-year business update for the period ended June 30, 2026. The company raised approximately $5.0 million in gross proceeds through private placement and ATM sales during Q2. It received roughly $3.2 million in new industrial purchase orders with revenue recognition expected starting in Q3 2026. Management issued revenue guidance of $900,000 to $1.1 million for Q3 and $1.0 million to $1.3 million for Q4 2026. The company advanced commercialization of its FDA-cleared SiNAPTIC Foot & Ankle Implant System via a Limited Use Release and established a distributor network. Additionally, SINTX completed construction of an advanced 3D printing facility and secured an extension on NIH grant funding. SINTX Technologies operates in the advanced ceramics industry, developing silicon nitride biomaterials and medical devices for orthopedic applications.
